These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1281 related articles for article (PubMed ID: 33651091)

  • 1. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
    JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Postreinduction Therapy Consolidation With Blinatumomab vs Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
    Brown PA; Ji L; Xu X; Devidas M; Hogan LE; Borowitz MJ; Raetz EA; Zugmaier G; Sharon E; Bernhardt MB; Terezakis SA; Gore L; Whitlock JA; Pulsipher MA; Hunger SP; Loh ML
    JAMA; 2021 Mar; 325(9):833-842. PubMed ID: 33651090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
    Litzow MR; Sun Z; Mattison RJ; Paietta EM; Roberts KG; Zhang Y; Racevskis J; Lazarus HM; Rowe JM; Arber DA; Wieduwilt MJ; Liedtke M; Bergeron J; Wood BL; Zhao Y; Wu G; Chang TC; Zhang W; Pratz KW; Dinner SN; Frey N; Gore SD; Bhatnagar B; Atallah EL; Uy GL; Jeyakumar D; Lin TL; Willman CL; DeAngelo DJ; Patel SB; Elliott MA; Advani AS; Tzachanis D; Vachhani P; Bhave RR; Sharon E; Little RF; Erba HP; Stone RM; Luger SM; Mullighan CG; Tallman MS
    N Engl J Med; 2024 Jul; 391(4):320-333. PubMed ID: 39047240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
    Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
    N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia.
    Locatelli F; Eckert C; Hrusak O; Buldini B; Sartor M; Zugmaier G; Zeng Y; Pilankar D; Morris J; von Stackelberg A
    Pediatr Blood Cancer; 2022 Aug; 69(8):e29715. PubMed ID: 35482538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab.
    Topp MS; Gökbuget N; Zugmaier G; Stein AS; Dombret H; Chen Y; Ribera JM; Bargou RC; Horst HA; Kantarjian HM
    Cancer; 2021 Feb; 127(4):554-559. PubMed ID: 33141929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study.
    Jabbour EJ; Gökbuget N; Kantarjian HM; Thomas X; Larson RA; Yoon SS; Ghobadi A; Topp MS; Tran Q; Franklin JL; Forman SJ; Stein AS
    Cancer; 2019 Dec; 125(23):4181-4192. PubMed ID: 31433496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extramedullary relapse and discordant CD19 expression between bone marrow and extramedullary sites in relapsed acute lymphoblastic leukemia after blinatumomab treatment.
    Demosthenous C; Lalayanni C; Iskas M; Douka V; Pastelli N; Anagnostopoulos A
    Curr Probl Cancer; 2019 Jun; 43(3):222-227. PubMed ID: 29895435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia.
    Llaurador G; Shaver K; Wu M; Wang T; Gillispie A; Doherty E; Craddock J; Read J; Yassine K; Morales E; George A; Steffin D; Krance R; Martinez C; Heslop H; Salem B
    Transplant Cell Ther; 2024 Feb; 30(2):217-227. PubMed ID: 37931800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.
    von Stackelberg A; Locatelli F; Zugmaier G; Handgretinger R; Trippett TM; Rizzari C; Bader P; O'Brien MM; Brethon B; Bhojwani D; Schlegel PG; Borkhardt A; Rheingold SR; Cooper TM; Zwaan CM; Barnette P; Messina C; Michel G; DuBois SG; Hu K; Zhu M; Whitlock JA; Gore L
    J Clin Oncol; 2016 Dec; 34(36):4381-4389. PubMed ID: 27998223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab consolidation and maintenance therapy in adults with relapsed/refractory B-precursor acute lymphoblastic leukemia.
    Rambaldi A; Huguet F; Zak P; Cannell P; Tran Q; Franklin J; Topp MS
    Blood Adv; 2020 Apr; 4(7):1518-1525. PubMed ID: 32289160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia.
    van der Sluis IM; de Lorenzo P; Kotecha RS; Attarbaschi A; Escherich G; Nysom K; Stary J; Ferster A; Brethon B; Locatelli F; Schrappe M; Scholte-van Houtem PE; Valsecchi MG; Pieters R
    N Engl J Med; 2023 Apr; 388(17):1572-1581. PubMed ID: 37099340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of blinatumomab for the treatment of B‑precursor acute lymphoblastic leukemia pediatric patients with high‑risk first‑relapse in Mexico.
    Diaz Martinez JP; de Maraumont TA; Camacho LM; Garcia L
    Leuk Res; 2024 Oct; 145():107560. PubMed ID: 39214018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of blinatumomab, a novel immunotherapy.
    Newman MJ; Benani DJ
    J Oncol Pharm Pract; 2016 Aug; 22(4):639-45. PubMed ID: 26607163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
    Foà R; Bassan R; Vitale A; Elia L; Piciocchi A; Puzzolo MC; Canichella M; Viero P; Ferrara F; Lunghi M; Fabbiano F; Bonifacio M; Fracchiolla N; Di Bartolomeo P; Mancino A; De Propris MS; Vignetti M; Guarini A; Rambaldi A; Chiaretti S;
    N Engl J Med; 2020 Oct; 383(17):1613-1623. PubMed ID: 33085860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.